The Chemours Company — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/249a309f-3dd3-412e-a45d-8dae64e1e961/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $5.8B | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-065201 |
| FY 2024 | $5.8B | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-021787 |
| FY 2023 | $6.1B | 2023-01-01 – 2023-12-31 | evidence 0000950170-25-021787 |
| FY 2022 | $6.8B | 2022-01-01 – 2022-12-31 | evidence 0000950170-25-021787 |
| FY 2021 | $6.3B | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-004791 |
| FY 2020 | $5.0B | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-005805 |
| FY 2019 | $5.5B | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-004829 |
| FY 2018 | $6.6B | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-003090 |
| FY 2017 | $6.2B | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-003090 |
| FY 2016 | $5.4B | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-003090 |
| FY 2015 | $5.7B | 2015-01-01 – 2015-12-31 | evidence 0001627223-16-000066 |
| FY 2014 | $6.4B | 2014-01-01 – 2014-12-31 | evidence 0001627223-16-000066 |
| FY 2013 | $6.9B | 2013-01-01 – 2013-12-31 | evidence 0001627223-16-000066 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).